Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Review Of Reviews: Drug Review Profiles Of 2011

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Each month, Pharmaceutical Approvals Monthly analyzes the FDA review process for a recent approval based on the NDA or BLA review documents. A detailed chronology of product development and listing of key reviewers accompany each profile.


Related Content

BI’s Tradjenta Lesson: Don’t Try To Use CV Trial To Score Head-To-Head Efficacy Evidence
FDA’s Benlysta Approval: A Lesson In Overcoming Unvalidated Endpoints
Human Genome Sciences Dodges Mortality Boxed Warning, REMS For Benlysta
Halaven Survival Data Was Gold-Standard Lining In Forced Shift From Accelerated To Full Approval
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
RE-LY Study Oversight Weaknesses A Factor In Pradaxa “Refuse-To-File” Action
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Egrifta Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need
FDA Finds Creative Labeling Solution For Egrifta Patient-Reported Outcomes Data





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts